Showing results (531-540 of 592) with videos related to
Sort By:
Pageof 60
European Journal of Cancer (Oxford, England : 1990)|August 31, 2022
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequencesFabrizio Tabbò, Lucia Anna Muscarella, Elisa Gobbini, et al.Cancer Discovery|July 12, 2020
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated MacrophagesIlaria Marigo, Rosalinda Trovato, Francesca Hofer, et al.Scientific Reports|October 6, 2025
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancerMarco Sposito, Lorenzo Belluomini, Riccardo Nocini, et al.Virchows Archiv : an International Journal of Pathology|January 3, 2024
Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectivesMichele Simbolo, Giovanni Centonze, Anastasios Gkountakos, et al.Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.Oncoimmunology|September 18, 2023
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patientsAnnalisa Adamo, Cristina Frusteri, Sara Pilotto, et al.Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.Cancer Immunology, Immunotherapy : CII|July 12, 2025
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational studyAlessandro Inno, Antonello Veccia, Ettore D'Argento, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialFrancois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.Journal of Clinical Medicine|February 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World StudyAntonello Veccia, Ettore D'Argento, Floriana Morgillo, et al.Pageof 60